← Leaderboards
Bassel El-Rayes
Emory University
$5,788,993
Attributed
$9,190,309
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,190,309 · 8
By mechanism
R01$5,961,341 · 4
P30$2,389,585 · 2
UH3$440,640 · 1
R21$398,743 · 1
Top collaborators
- Gregory B. Lesinski7 shared
- Asfar S Azmi5 shared
- Harrison Kim2 shared
- Zhi-Ren Liu2 shared
- Ashiq Masood2 shared
Most similar at Emory University
Same institution · by research overlap
- Laura R Stroud$29,941,854
- Jesse Roman-Rodriguez$12,571,619
- Carla J Berg$13,165,045
- Gregory B. Lesinski$9,344,242
- Cherry P Wongtrakool$1,454,098
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMalignant NeoplasmsProgramsResponseClinical ResearchToxic EffectTumorPhysiciansInnovationInstitutesBiopsyProteinsResistanceBaseBloodMonitorNovel TherapeuticsTreatment ResponsePreclinical StudySignal TransductionIn VivoInstitutionTissuesCancer Center Support Grant
Grant awards (30)
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer$657,895
R01 · FY2025 · CA
ProAgio in Pancreatic Cancer$577,819
R01 · FY2025 · CA · contact PI
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer$669,747
R01 · FY2024 · CA
ProAgio in Pancreatic Cancer$590,094
R01 · FY2024 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$336,000
R01 · FY2024 · CA
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response$440,640
UH3 · FY2023 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$346,592
R01 · FY2023 · CA
Targeting immune stroma interactions in pancreatic cancer$341,667
R01 · FY2023 · CA
Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade$179,252
R21 · FY2023 · CA
A novel therapy for pancreatic neuroendocrine tumors$346,572
R01 · FY2022 · CA
Targeting immune stroma interactions in pancreatic cancer$340,118
R01 · FY2022 · CA
Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade$219,491
R21 · FY2022 · CA
A novel therapy for pancreatic neuroendocrine tumors$353,627
R01 · FY2021 · CA
Targeting immune stroma interactions in pancreatic cancer$345,477
R01 · FY2021 · CA
Clinical Protocol and Data Management$308,479
P30 · FY2021 · CA · contact PI
A novel therapy for pancreatic neuroendocrine tumors$365,962
R01 · FY2020 · CA
Targeting immune stroma interactions in pancreatic cancer$346,416
R01 · FY2020 · CA
Clinical Protocol and Data Management$308,479
P30 · FY2020 · CA · contact PI
Targeting immune stroma interactions in pancreatic cancer$343,355
R01 · FY2019 · CA
Clinical Protocol and Data Management$308,479
P30 · FY2019 · CA · contact PI
Clinical Protocol and Data Management$308,479
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$13,365
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$4,861
P30 · FY2018 · CA · contact PI
Clinical Protocol and Data Management$338,339
P30 · FY2017 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$162,453
P30 · FY2016 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$162,453
P30 · FY2015 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$165,344
P30 · FY2014 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$148,003
P30 · FY2013 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$2,339
P30 · FY2013 · CA · contact PI
CLINICAL TRIALS SHARED RESOURCE$158,512
P30 · FY2012 · CA · contact PI